M.D., Medical Oncologist and Clinical Director, Molecular Tumor Board and Personalized Medicine Initiative, Inova Health System
Dr. Cannon is a medical oncologist focused on GI oncology and is the clinical director and moderator of the weekly molecular tumor board at Inova, which has met weekly since March 2016. He is the site principal inves-tigator for multiple cooperative group, industry sponsored, and investigator initiated clinical trials and has been first author of articles in The Oncologist, The Journal of Clinical Oncology, and others. Dr. Cannon was the chief fellow of hematology/oncology at New York University (NYU). He was voted fellow of the year at NYU during each of his last two years there. A native of New Jersey, Dr. Cannon is married with two sons. His wife, Amy, works for Save the Children. In his spare time, he likes to play sports and read books. He was a member of two Division I basketball teams (Uni-versity of Utah and Brigham Young University) in the 1990s and continues to be a huge basketball fan. He is fluent in Mandarin.
Precision Medicine within the Community Setting
Despite the clinical benefits of precision medicine, widespread uptake has been limited within the community setting. This talk will provide some insight into the clinical utility of implementing NGS within a community institution, and show how Oncomine Assays play an important role in the field of precision medicine.